Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group,Pediatric Blood & Cancer

当前位置： X-MOL 学术 › Pediatr. Blood Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group
Pediatric Blood & Cancer ( IF 2.4 ) Pub Date : 2021-09-02 , DOI: 10.1002/pbc.29313
Kelly D Getz _{1,

2} , Todd A Alonzo ₃ , Lillian Sung ₄ , Soheil Meshinchi ₅ , Robert B Gerbing ₆ , Susana Raimondi ₇ , Betsy Hirsch ₈ , Michael Loken ₉ , Lisa Eidenschink Brodersen ₉ , Samir Kahwash ₁₀ , John Choi ₇ , E Anders Kolb ₁₁ , Alan Gamis ₁₂ , Richard Aplenc _{1,

2}

Affiliation

Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, Pennsylvania, USA.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
University of Southern California, Los Angeles, California, USA.
The Hospital for Sick Children, Toronto, Ontario, Canada.
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Children's Oncology Group, Monrovia, California, USA.
St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
University of Minnesota, Minneapolis, Minnesota, USA.
Hematologics Inc, Seattle, Washington, USA.
Nationwide Children's Hospital, Columbus, Ohio, USA.
Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA.
Children's Mercy Hospital and Clinics, Kansas City, Missouri, USA.